Activatable Cytokine Constructs Protease Cleavage

The patent applies local quality by designing cytokine constructs with tissue-specific activation properties. The constructs remain inactive in healthy tissues and are selectively activated only in diseased tissues through protease cleavage, creating different functional qualities in different locations. This resolves the contradiction by maintaining high therapeutic efficacy at the target site while minimizing systemic toxicities in healthy organs.

The patent uses protease-cleavable linkers as intermediaries between the cytokine and dimerization domain. These intermediaries are intact during systemic circulation (preventing activation) and are cleaved by disease-associated proteases at the target site (enabling activation). This intermediary mechanism allows the cytokine to traverse from systemic administration to localized action, resolving the contradiction between systemic delivery and localized effect.

The patent changes the activation state parameter of the cytokine from permanently active to conditionally active. By incorporating protease-cleavable linkers, the cytokine construct transitions from an inactive dormant state during circulation to an active state only upon protease cleavage at the disease site. This parameter change enables effective dosing without proportionally increasing systemic toxicity, as the cytokine remains inactive in the bloodstream.

The patent applies preliminary action by pre-positioning the cytokine in an inactive construct form that is stable during circulation. The activation event (protease cleavage) occurs preliminarily at the target site before the cytokine exerts its full therapeutic effect, ensuring that high concentrations are achieved only where needed. This preliminary localization of activation prevents premature systemic effects while enabling potent local therapy.

The patent applies dynamics by creating a cytokine construct that changes its functional state in response to the disease microenvironment. The construct is dynamically inactive during systemic circulation and becomes dynamically active only in the presence of disease-associated proteases. This dynamic switching mechanism provides temporal and spatial control over cytokine activity, dramatically improving targeting specificity while maintaining biological efficacy at the target site.

The patent segments the cytokine construct into distinct functional modules: the cytokine domain, the protease-cleavable linker, and the dimerization domain. This segmentation allows the cytokine to be delivered systemically in an inactive state and activated locally through cleavage of the intermediate linker segment. The segmented design enables independent optimization of each module's function, improving both targeting specificity and therapeutic efficacy.